Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Proposes Easing Price Controls For Some Makers Of Key Drugs

This article was originally published in PharmAsia News

Executive Summary

India's Cabinet ministers have proposed a certification process to give makers of key drugs an added advantage in setting prices. The proposal sent to the Law Ministry would offer a "gold standard" certificate to companies that meet certain conditions, including having at least 200 scientists on staff. Another requirement would be to have at least one manufacturing facility approved by two foreign regulators and to spend at least 5 percent of turnover on research and development. The certificate would allow them to claim a 200 percent maximum allowable post-manufacturing expense, compared with 150 percent for unqualified firms. The change would affect prices on 354 lifesaving drugs the government wants to bring under price controls. (Click here for more

You may also be interested in...

Siemens Healthineers Gets Varian In 16.4Bn Deal To Enter Cancer Treatment Market

In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.

Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.

Sun Loses Shine In Q1, Testing Times In US

Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts